Multiple Myeloma: Adding Daratumumab to Carfilzomib/Dexamethasone Enhances Efficacy

Results from the phase 3 CANDOR trial show that for relapsed/refractory multiple myeloma, adding daratumumab (D) to carfilzomib/dexamethasone (Kd) increases efficacy compared with Kd alone. "Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma," write the study investigators in their publication in The Lancet, led by Meletios Dimopoulos, MD, Professor and Chairman of Clinical Therapeutics at the Na...

Breast Cancer in Older Patients With Comorbidities: Chemotherapy Improves Survival

In older patients with multiple comorbidities and estrogen receptor (ER)-positive, node-positive breast cancer, chemotherapy improves survival, according to a study published today in JAMA Oncology. "Breast cancer risk and the incidence of comorbidities increase with age. Treatment of elderly patients with significant comorbidities is challenging," write the investigators, led by first author Nina Tamirisa, MD, Assistant Professor of Breast Surgical Oncology at The University of Texas MD Anderso...

COVID-19 and Cancer: Age, Comorbidities Linked to Outcome

During the early stages of the pandemic, measures taken to prevent patients with cancer from contracting COVID-19 included limiting hospital attendance and delaying systemic anticancer treatment. "Whilst dictated by the necessary adoption of a precautionary principle in the context of rapidly escalating viral transmission, these measures rested on the assumption of a detrimental effect of cancer and active anticancer therapy on outcomes from SARS-CoV-2 infection," write the authors of a newly pu...

Follicular Lymphoma: Hard to Improve on Bendamustine/Rituximab Induction

The latest data from the three-arm randomized phase 2 ECOG-ACRIN E2408 trial, which sought to improve upon frontline bendamustine/rituximab (BR) induction therapy followed by rituximab maintenance in untreated high-risk follicular lymphoma (FL), have yielded disappointing results: neither adding bortezomib to BR induction nor adding lenalidomide following BR induction improves outcomes. For the trial, 289 patients were randomized to receive either BR induction followed by two-year rituximab main...

Treatment Advances in Gastrointestinal Stromal Tumor With Shreyaskumar Patel, MD

The fact that gastrointestinal stromal tumor (GIST) is a rare tumor type, with an estimated incidence of 3,300 to 6,000 new cases per year in the United States, can make it more challenging for oncologists and other members of the cancer care team to stay up to date on the latest therapeutic developments. Treatment for GIST has seen exciting progress this year, with two new FDA approvals for metastatic disease. This episode of Oncology Data Advisor features Dr. Shreyaskumar Patel, Robert R. Herr...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.